Have the Home Office made the correct decision not allowing the use of Cannabis Oil?
Alfie Dingley's mum is putting across a strong argument against their decision today on TV & Radio.
www.bbc.co.uk/programmes/p05yncmy
I heard it. Very sad. I have done a small amount of lab research on cannabis, and one of my PhD students did 3 year's in the lab working on CB1 and CB2 receptors in the cardiovascuar system. I have lots of contacts in the pharmaceutical industry who have worked on it. Sadly, despite much interest and some controlled clinical trials, it does nothing very much outside the psychopharm area. I hadn't read the evidence on its effects in epilepsy (which is related to psychopharm in as much as both are 'the brain'). There are no 'rationing' issues as there are with some monoclonal antibodies. My understanding is the refusal to allow its use here would largely be about the use of yer actual cannabis (a naughty drug compared with rather the non psychotropic derivative such as cannabidiol).
I have dug around for the original research. I use web of science regularly and know what peer reviewed research publications look like. Unfortunately it does not look very convincing. Yes there is a trial in Dravet syndrome, published in a top journal (New England Journal of Medicine). BUT it is on cannabidiol (not cannabis, the plant extract that contains the psychotropic chemical delta-9-THC). The most up to date viewpoint is published in Feb 2018 in another credible journal (see below). Note that 'cannabinoid' means a chemical derived from the plant, or a synthetic related to a cannabinoid. Here is the abstract:
"Over the past decade there has been an increasing interest in using cannabinoids to treat a range of epilepsy syndromes following reports of some remarkable responses in individual patients. The situation is complicated by the fact that these agents do not appear to work via their attachment to endogenous cannabinoid receptors. Their pharmacokinetics are complex, and bioavailability is variable, resulting in difficulty in developing a suitable formulation for oral delivery. Drug interactions also represent another complication in their everyday use. Nevertheless, recent randomized, placebo-controlled trials with cannabidiol support its efficacy in Dravet and Lennox-Gastaut syndromes. Further placebo-controlled studies are underway in adults with focal epilepsy using cannabidivarin. The many unanswered questions in the use of cannabinoids to treat epileptic seizures are briefly summarized in the conclusion."
I can't find any evidence that cannabis itself has any value in this condition. Yes of course there are individual testimonies for improvement in outcome for countless conditions and countless drugs (as appears to be the case here) but this is not evidence. Given that cannabis is a schedule 1 drug there is no way it can be approved for use in individual cases, no matter how heart-rending.
This may change if we go the way of Canda and other places and stop classing cannabis along with other schedule 1 drugs. But we are a long way away from this. Lack of evidence of benefit (as a treatment for Dravet), and well established evidence for harm kills it for now.